News & storiesCheck out our latest stories2022-01-25Press releaseAs Omicron Spreads Nationally, Octapharma’s fibryga® & Octaplas™ Become Increasingly Important Replacement TherapiesMedical Providers Should Consider Replacing Cryoprecipitate and Fresh Frozen Plasma with Octaplas™ and fibryga® if Supplies Become Depleted2021-12-07Press releaseFDA Approves Octapharma’s cutaquig® 16.5% for Pediatric PI Patients, Providing Flexible Treatment OptionsFamilies, Providers Can Utilize Flexible Infusion Schedule to Meet Patient Needs2021-08-30Press releaseFDA Orphan Drug Approval: Octapharma’s Octagam® 10% Receives 7 Years of Market Exclusivity for Adult DermatomyositisOctagam® 10% Expected to Become the First Treatment Option for Adults with Rare Immune-mediated Inflammatory Disease2021-07-20Press releaseFDA Approves Octapharma's Octagam®10% for Adult DermatomyositisFDA Approval Based on Positive Results of International, Multi-center ProDERM StudyShow more
2022-01-25Press releaseAs Omicron Spreads Nationally, Octapharma’s fibryga® & Octaplas™ Become Increasingly Important Replacement TherapiesMedical Providers Should Consider Replacing Cryoprecipitate and Fresh Frozen Plasma with Octaplas™ and fibryga® if Supplies Become Depleted
2021-12-07Press releaseFDA Approves Octapharma’s cutaquig® 16.5% for Pediatric PI Patients, Providing Flexible Treatment OptionsFamilies, Providers Can Utilize Flexible Infusion Schedule to Meet Patient Needs
2021-08-30Press releaseFDA Orphan Drug Approval: Octapharma’s Octagam® 10% Receives 7 Years of Market Exclusivity for Adult DermatomyositisOctagam® 10% Expected to Become the First Treatment Option for Adults with Rare Immune-mediated Inflammatory Disease
2021-07-20Press releaseFDA Approves Octapharma's Octagam®10% for Adult DermatomyositisFDA Approval Based on Positive Results of International, Multi-center ProDERM Study
Patient engagementOctapharma takes an active role in our communityWe sponsor and support organizations worldwide.Learn how we engage with patients
Our productsProductsLearn more about our products to treat rare diseases and other coagulopathies and bleeding disorders.Learn more